Pande Vijay Satyanand

Director Pande Vijay Satyanand bought 219,195 shares for $4,329,019.37 across 3 transactions (Oct 1-3) at $19.75 blended average; concurrent cluster buy by 4 other insiders.

Pande Vijay Satyanand, a director at BioAge Labs, executed 3 separate purchases totaling 219,195 shares for $4,329,019.37 between October 1 and October 3, 2024, increasing his holdings by 24.4% from 900,000 shares to 1,119,195 shares. The blended average purchase price of $19.75 sits 5.3% below the current price of $20.86, though comparisons are constrained by the company's recent listing status (6 trading days). Notably, 4 other insiders also bought within the same 14-day window, forming a cluster purchase pattern that suggests coordinated conviction among the insider group. The scale of Pande's personal acquisition—a significant near-$4.3M commitment—combined with the simultaneous buying activity by multiple officers and directors, indicates material confidence in the stock near its market introduction.

Director Pande Vijay Satyanand bought 900,000 shares of BIOA at $18.00 ($16.2M) post-IPO; 4 other insiders bought within 14 days.

Director Pande Vijay Satyanand purchased 900,000 shares at $18.00 for a total value of $16,200,000.00, establishing an initial position in BioAge Labs just 2 trading days after the company's recent IPO listing. This transaction carries the FLAG that it involves a conversion of derivative securities, so the Form 4 Table I shares_after figure does not represent the director's total position—the full holding picture resides in Table II derivatives, which are not yet populated in the database. Notably, 4 other insiders also executed purchases within the past 14 days, forming a coordinated insider buying cluster immediately following the listing. This pattern of multi-insider acquisition activity in the IPO window is material and warrants investor attention as a signal of confidence from multiple members of the company's leadership team during the critical early-trading period.